Track OCS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$756.93M
Enterprise Value$635.22M
Revenue (TTM)$622.74K
Net Income (TTM)-$117.46M
Free Cash Flow (TTM)-$78.06M
Financial Health
Cash$273.53M
Net Debt-$121.72M
Debt Ratio0.51
Debt to Equity0.63
Interest Coverage-126.8
Valuation (TTM)
Price to Sales1215.48
Price to Earnings-6.44
EV to EBITDA-5.46
Price to Book3.12
Price to Free Cash Flow-9.7
Margins (TTM)
Gross Profit Margin-2889.37%
EBITDA Margin-18676.35%
Operating Income Margin-16740.95%
Net Income Margin-18861.29%
Free Cash Flow Margin-12534.15%
Returns (5Y Avg)
Return on Invested Capital-75.23%
Return on Assets-55.05%
Return on Equity-37.97%
Return on Total Capital-75.23%
Return on Capital Employed-74.88%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (3Y)
Revenue-98.97%
Diluted EPS-8.20%
Total Debt-84.00%
Capital Expenditures-56.73%
Free Cash Flow-99.69%
CAGR (1Y)
Revenue-100.00%
Diluted EPS36.36%
Total Debt59.55%
Capital Expenditures24.99%
Free Cash Flow-100.00%
$11.77+$0.04|+0.34%
Last updated: Jul 21, 2:19 PM ET
52W High$34.48
52W Low$10.52
50D SMA$17.91
200D SMA$22.37
Volume144.87K
Oculis Holding AG Ordinary shares
Bahnhofstrasse 20, Zug, Switzerland, 6300
IPO
2023
Employees
60
Industry
Biotechnology
Sector
Healthcare
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0